EW - Edwards Lifesciences: EPS Acceleration Shares Poised To Rally (Rating Upgrade)

2024-05-09 00:31:25 ET

Summary

• Health Care sector performance in the S&P 500 has been mixed, with some companies struggling while Eli Lilly dominates amid a focus on GLP-1s.
• Edwards Lifesciences Corporation is a leader in the transcatheter heart valve replacement market and features under-the-radar EPS growth trends.
• EW reported strong Q1 results and is expected to continue growing in its TAVR and TMTT segments.
• I am upgrading the stock and highlighting key price levels to monitor.

While much of the S&P 500 has enjoyed robust gains over the past 12 months, the Health Care sector has been a mixed bag. At home, Eli Lilly ( LLY ) dominates, now in the top 10 in terms of largest domestic companies by market cap, while other drug manufacturers have struggled to execute and build their pipelines. Medical Devices firms likewise have not found a solid footing as the sector realigns itself post-pandemic. ...

For further details see: